Toremifene
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Toremifene: From Unrecorded Original Indication to HIV Infectious Disease
One-Sentence Summary
Toremifene is a selective estrogen receptor modulator (SERM), historically related to tamoxifen and used in breast cancer treatment; its original approved indication is not documented in the current evidence pack, and the drug is not marketed in Germany. The TxGNN model predicts it may be effective for HIV infectious disease, but this is currently supported by only 1 in vitro mechanistic publication and no clinical trials — the evidence base is very preliminary.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L5 |
| Germany Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on the available literature, toremifene is a selective estrogen receptor modulator (SERM) pharmacologically related to the breast cancer drug tamoxifen.
The only supporting publication (PMID 24520056) is an in vitro mechanistic study showing that estrogen receptor antagonists (including tamoxifen and toremifene) can directly bind fungal EF-hand (calcium-binding) proteins, giving them anti-cryptococcal activity against Cryptococcus neoformans — a common opportunistic infection in HIV/AIDS patients — rather than a direct antiretroviral effect on HIV itself.
This means the mechanistic link between toremifene and the predicted indication "HIV infectious disease" is indirect: the drug title and study content concern antifungal activity against an HIV-associated opportunistic pathogen, not the HIV virus directly. The high TxGNN score (99.41%) likely reflects knowledge-graph proximity between HIV and cryptococcosis (a known comorbidity) rather than a direct antiviral mechanism. No clinical trial evidence exists to support this prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24520056 | 2014 | In vitro mechanistic study | mBio | Estrogen receptor antagonists (tamoxifen, toremifene) show fungicidal activity against Cryptococcus neoformans by binding fungal EF-hand proteins; synergizes with fluconazole and amphotericin B in vitro — relevant to HIV-associated cryptococcosis, not HIV itself |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L5 — the only support is a single in vitro mechanistic study with an indirect link (antifungal activity against an HIV-associated opportunistic infection, not a direct antiviral mechanism), and there are zero clinical trials. This does not meet the threshold to advance to safety screening (S1).
To proceed, the following is needed:
- TFDA/BfArM package insert with warnings and contraindications (currently blocking — DG001)
- Confirmed mechanism of action (DrugBank query — DG002)
- Direct evidence of anti-HIV or anti-cryptococcal activity in vivo/clinically, not just in vitro
- Clarification of toremifene's original approved indication for comparative mechanistic analysis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.